LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_001040108.2:c.4289_4293del
MLH3
· NP_001035197.1:p.(Arg1430LeufsTer7)
· NM_001040108.2
GRCh37: chr14:75483853 AGAGAC>A
·
GRCh38: chr14:75017150 AGAGAC>A
Gene:
MLH3
Transcript:
NM_001040108.2
Final call
VUS
PM2 moderate
Variant details
Gene
MLH3
Transcript
NM_001040108.2
Protein
NP_001035197.1:p.(Arg1430LeufsTer7)
gnomAD AF
8.679705237210145e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Likely Oncogenic
Classification rationale
Interpretation summary
Generated evidence synthesis
1
VUS: PM2 moderate is supported by the extremely low population frequency of 14/1,612,958 alleles in gnomAD v4.1, with zero homozygotes.
Final determination:
Under the generic ACMG/AMP 2015 fallback, one moderate criterion alone does not meet any pathogenic, likely pathogenic, likely benign, or benign combination threshold, so the final call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | Not met | Met at moderate strength: the terminal-exon frameshift escapes NMD and removes 18 of 1454 residues (1.24%), triggering the named last-exon/NMD-escape downgrade. (PVS1 changed from met (moderate) to not_met) |
pvs1_gene_context
pvs1_variant_assessment
pvs1_generic_framework
PMID:25741868
|
| PS1 | N/A | Not applicable: PS1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PS2 | Not assessed | Not assessed: no documented proband phenotype, family-history assessment, or confirmed maternity and paternity is available for this variant. |
clinvar
|
| PS3 | Not assessed | Not assessed: the only functional study used a different truncated MLH3 construct and did not test c.4289_4293del. |
PMID:10615123
|
| PS4 | Not met | Not met: no affected-case count or case-control OR is available, and reviewed literature provides no exact-variant enrichment evidence despite gnomAD frequencies of 1/251454 and 14/1612958. |
gnomad_v2
gnomad_v4
PMID:34043773
|
| PM1 | N/A | Not applicable: PM1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PM2 | Met | Met at Moderate: gnomAD v4.1 observes 14/1,612,958 alleles (AF 8.68e-06), below the <=0.0001 extremely-low-frequency PM2 cutoff, with zero homozygotes. |
gnomad_v4
gnomad_v2
|
| PM3 | Not assessed | Not assessed: no documented parental testing, phase, affected-proband observation, or pathogenic allele is available for NM_001040108.2:c.4289_4293del. |
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a frameshift variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | N/A | Not applicable: PM5 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PM6 | Not assessed | Not assessed: no report documents an assumed de novo occurrence or provides the proband and parental information needed to evaluate it. |
clinvar
|
| PP1 | Not assessed | Not assessed: no affected relatives or informative meioses are reported to demonstrate co-segregation of the variant with disease. |
clinvar
|
| PP2 | N/A | Not applicable: PP2 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| PP3 | N/A | Not applicable: the variant is a frameshift, outside PP3's missense or splice-region/intronic scope. |
|
| PP4 | Not assessed | Not assessed: the patient's phenotype and family history are unavailable, so disease-specific phenotype specificity cannot be judged. |
|
| PP5 | Not met | Not met: ClinVar has two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Pathogenic or Likely pathogenic classification. |
clinvar
PMID:34043773
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.88e-06, far below the 0.05 BA1 threshold, with the qualifying NFE population contributing 1,179,980 observed alleles. |
gnomad_v4
gnomad_v2
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 6.88e-06 (0.000688%), far below the generic BS1 threshold of 0.01 (1%). |
gnomad_v4
PMID:25741868
|
| BS2 | Not met | Not met: gnomAD v4.1 reports zero homozygotes for the variant, and no documented healthy-adult observation establishes BS2 for a dominant, recessive, or X-linked disorder. |
gnomad_v4
gnomad_v2
|
| BS3 | Not assessed | Not assessed: no assay tested c.4289_4293del and demonstrated no damaging effect on MLH3 protein function or splicing. |
PMID:10615123
|
| BS4 | Not assessed | Not assessed: no affected relatives are reported whose genotypes demonstrate that the variant fails to segregate with disease. |
clinvar
|
| BP1 | N/A | Not applicable: BP1 requires a missense variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
| BP2 | Not assessed | Not assessed: no documented cis or trans phase result with a pathogenic variant is available for NM_001040108.2:c.4289_4293del. |
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a frameshift variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | N/A | Not applicable: the variant is a frameshift, for which a no-impact splice prediction cannot support BP4. |
|
| BP5 | Not assessed | Not assessed: no case-level alternate molecular basis or alternate pathogenic diagnosis is documented for this exact variant. |
|
| BP6 | Not met | Not met: ClinVar shows two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Benign or Likely benign expert-panel classification. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a frameshift variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.